Brian Abrahams
Stock Analyst at RBC Capital
(3.85)
# 819
Out of 4,479 analysts
332
Total ratings
51.93%
Success rate
7.25%
Average return
Main Sectors:
30 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Reiterates: Outperform | $317 | $228.82 | +38.54% | 28 | Jun 27, 2024 | |
| ITCI Intra-Cellular Therapies | Reiterates: Outperform | $103 | $68.54 | +50.28% | 14 | Jun 25, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Outperform | $1,229 | $1,044.66 | +17.65% | 21 | Jun 24, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Sector Perform | $142 → $182 | $154.20 | +18.03% | 20 | Jun 21, 2024 | |
| XENE Xenon Pharmaceuticals | Reiterates: Outperform | $55 | $36.56 | +50.44% | 12 | Jun 18, 2024 | |
| GILD Gilead Sciences | Reiterates: Sector Perform | $74 | $68.40 | +8.19% | 19 | Jun 14, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $77 → $82 | $48.01 | +70.80% | 3 | Jun 11, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $424 → $421 | $473.78 | -11.14% | 43 | Jun 11, 2024 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Outperform | $22 | $6.96 | +216.09% | 9 | Jun 5, 2024 | |
| HOOK HOOKIPA Pharma | Reiterates: Outperform | $5 | $0.58 | +759.70% | 8 | May 21, 2024 | |
| PLRX Pliant Therapeutics | Maintains: Outperform | $54 → $45 | $10.60 | +324.53% | 11 | May 7, 2024 | |
| CTNM Contineum Therapeutics | Initiates: Outperform | $30 | $20.69 | +45.00% | 1 | Apr 30, 2024 | |
| SAGE Sage Therapeutics | Maintains: Sector Perform | $26 → $15 | $10.82 | +38.63% | 17 | Apr 26, 2024 | |
| MRNS Marinus Pharmaceuticals | Downgrades: Sector Perform | $24 → $3 | $1.19 | +152.10% | 7 | Apr 15, 2024 | |
| APLT Applied Therapeutics | Reiterates: Outperform | $12 | $4.35 | +175.86% | 2 | Apr 11, 2024 | |
| NMRA Neumora Therapeutics | Reiterates: Outperform | $31 | $9.80 | +216.33% | 3 | Mar 28, 2024 | |
| INCY Incyte | Reiterates: Sector Perform | $65 | $59.02 | +10.13% | 12 | Mar 25, 2024 | |
| PTCT PTC Therapeutics | Reiterates: Sector Perform | $28 | $30.39 | -7.86% | 13 | Mar 8, 2024 | |
| IGMS IGM Biosciences | Reiterates: Outperform | $21 | $6.40 | +228.13% | 11 | Mar 8, 2024 | |
| ETNB 89bio | Maintains: Sector Perform | $15 → $14 | $7.60 | +84.21% | 12 | Mar 1, 2024 | |
| PRTA Prothena Corporation | Maintains: Sector Perform | $36 → $35 | $20.39 | +71.65% | 7 | Feb 16, 2024 | |
| NBIX Neurocrine Biosciences | Maintains: Sector Perform | $128 → $121 | $137.49 | -11.99% | 11 | Nov 10, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $4 → $3 | $0.80 | +275.00% | 7 | Nov 3, 2023 | |
| ENTA Enanta Pharmaceuticals | Maintains: Sector Perform | $25 → $15 | $13.45 | +11.52% | 14 | Oct 2, 2023 | |
| BCRX BioCryst Pharmaceuticals | Reiterates: Outperform | $10 | $6.55 | +52.67% | 9 | Sep 25, 2023 | |
| GLPG Galapagos NV | Maintains: Sector Perform | $43 → $41 | $25.34 | +61.80% | 9 | May 8, 2023 | |
| ATAI Atai Life Sciences | Maintains: Sector Perform | $12 → $9 | $1.30 | +592.31% | 3 | Mar 31, 2022 | |
| MRUS Merus | Maintains: Sector Perform | n/a | $53.09 | - | 3 | Nov 3, 2021 | |
| NBSE NeuBase Therapeutics | Initiates: Outperform | n/a | $0.38 | - | 1 | Jun 16, 2020 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Buy | n/a | $40.96 | - | 2 | Dec 4, 2017 |
Biogen
Jun 27, 2024
Reiterates: Outperform
Price Target: $317
Current: $228.82
Upside: +38.54%
Intra-Cellular Therapies
Jun 25, 2024
Reiterates: Outperform
Price Target: $103
Current: $68.54
Upside: +50.28%
Regeneron Pharmaceuticals
Jun 24, 2024
Reiterates: Outperform
Price Target: $1,229
Current: $1,044.66
Upside: +17.65%
Sarepta Therapeutics
Jun 21, 2024
Maintains: Sector Perform
Price Target: $142 → $182
Current: $154.20
Upside: +18.03%
Xenon Pharmaceuticals
Jun 18, 2024
Reiterates: Outperform
Price Target: $55
Current: $36.56
Upside: +50.44%
Gilead Sciences
Jun 14, 2024
Reiterates: Sector Perform
Price Target: $74
Current: $68.40
Upside: +8.19%
Corbus Pharmaceuticals Holdings
Jun 11, 2024
Maintains: Outperform
Price Target: $77 → $82
Current: $48.01
Upside: +70.80%
Vertex Pharmaceuticals
Jun 11, 2024
Maintains: Sector Perform
Price Target: $424 → $421
Current: $473.78
Upside: -11.14%
Mind Medicine (MindMed)
Jun 5, 2024
Reiterates: Outperform
Price Target: $22
Current: $6.96
Upside: +216.09%
HOOKIPA Pharma
May 21, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.58
Upside: +759.70%
Pliant Therapeutics
May 7, 2024
Maintains: Outperform
Price Target: $54 → $45
Current: $10.60
Upside: +324.53%
Contineum Therapeutics
Apr 30, 2024
Initiates: Outperform
Price Target: $30
Current: $20.69
Upside: +45.00%
Sage Therapeutics
Apr 26, 2024
Maintains: Sector Perform
Price Target: $26 → $15
Current: $10.82
Upside: +38.63%
Marinus Pharmaceuticals
Apr 15, 2024
Downgrades: Sector Perform
Price Target: $24 → $3
Current: $1.19
Upside: +152.10%
Applied Therapeutics
Apr 11, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.35
Upside: +175.86%
Neumora Therapeutics
Mar 28, 2024
Reiterates: Outperform
Price Target: $31
Current: $9.80
Upside: +216.33%
Incyte
Mar 25, 2024
Reiterates: Sector Perform
Price Target: $65
Current: $59.02
Upside: +10.13%
PTC Therapeutics
Mar 8, 2024
Reiterates: Sector Perform
Price Target: $28
Current: $30.39
Upside: -7.86%
IGM Biosciences
Mar 8, 2024
Reiterates: Outperform
Price Target: $21
Current: $6.40
Upside: +228.13%
89bio
Mar 1, 2024
Maintains: Sector Perform
Price Target: $15 → $14
Current: $7.60
Upside: +84.21%
Prothena Corporation
Feb 16, 2024
Maintains: Sector Perform
Price Target: $36 → $35
Current: $20.39
Upside: +71.65%
Neurocrine Biosciences
Nov 10, 2023
Maintains: Sector Perform
Price Target: $128 → $121
Current: $137.49
Upside: -11.99%
Karyopharm Therapeutics
Nov 3, 2023
Maintains: Outperform
Price Target: $4 → $3
Current: $0.80
Upside: +275.00%
Enanta Pharmaceuticals
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $13.45
Upside: +11.52%
BioCryst Pharmaceuticals
Sep 25, 2023
Reiterates: Outperform
Price Target: $10
Current: $6.55
Upside: +52.67%
Galapagos NV
May 8, 2023
Maintains: Sector Perform
Price Target: $43 → $41
Current: $25.34
Upside: +61.80%
Atai Life Sciences
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $1.30
Upside: +592.31%
Merus
Nov 3, 2021
Maintains: Sector Perform
Price Target: n/a
Current: $53.09
Upside: -
NeuBase Therapeutics
Jun 16, 2020
Initiates: Outperform
Price Target: n/a
Current: $0.38
Upside: -
Ultragenyx Pharmaceutical
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $40.96
Upside: -